Prothena Corp Public (PRTA) Other financing activities (2012 - 2024)
Prothena Corp Public (PRTA) posted quarterly Other financing activities of -$1000.0 for Q4 2024, down 100.18% year-over-year from $548000.0 in Q1 2024, and down 100.23% quarter-over-quarter from $427000.0 in Q3 2024.
Prothena Corp Public (PRTA) Other financing activities (2012 - 2024) Analysis & Trends
Prothena Corp Public's Other financing activities history runs 12 years deep, the most recent figure standing at -$1000.0 for Q4 2024.
- In Q4 2024, Other financing activities fell 100.18% year-over-year to -$1000.0; the TTM figure through Sep 2025 stood at -$1000.0 (down 100.04% YoY), while the FY2024 annual figure was $1.9 million, down 91.14% from the prior year.
- Other financing activities for Q4 2024 stood at -$1000.0, down from $427000.0 in the prior quarter.
- The five-year high for Other financing activities was $15.6 million in Q2 2023, with the low at -$1000.0 in Q4 2024.
- The 5-year median for Other financing activities is $1.7 million (2021), against an average of $3.2 million.
- The sharpest annual moves came in 2021 and 2024: Other financing activities jumped 6368.75% in 2021, then plunged 100.18% in 2024.
- Prothena Corp Public's Other financing activities stood at $64000.0 in 2020, then surged by 2790.62% to $1.8 million in 2021, then surged by 528.7% to $11.6 million in 2022, then sank by 95.29% to $548000.0 in 2023, then slumped by 100.18% to -$1000.0 in 2024.
- Business Quant data shows PRTA's Other financing activities at -$1000.0 in Q4 2024, $427000.0 in Q3 2024, and $591000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Prothena Corp Public | 458.45 Mn | 170.25 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -1,000.00 |
| Dec 31, 2024 | -1,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Sep 30, 2024 | 427,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Jun 30, 2024 | 591,000.00 |
| Mar 31, 2024 | 890,000.00 |
| Mar 31, 2024 | 890,000.00 |
| Dec 31, 2023 | 548,000.00 |
| Dec 31, 2023 | 548,000.00 |
| Sep 30, 2023 | 2.78 Mn |
| Sep 30, 2023 | 2.78 Mn |
| Jun 30, 2023 | 15.59 Mn |
| Jun 30, 2023 | 15.59 Mn |
| Mar 31, 2023 | 2.60 Mn |
| Mar 31, 2023 | 2.60 Mn |
| Dec 31, 2022 | 11.63 Mn |
| Dec 31, 2022 | 11.63 Mn |
| Sep 30, 2022 | 4.30 Mn |
| Sep 30, 2022 | 4.30 Mn |